FOLH1 and Lymphadenopathy: However, based on the radiological and biochemical workup done after the second dose in January 2024, the patient was considered not responding to 177Lu-PSMA therapy since his general health deteriorated, his PSA level kept on rising reaching 528 ng/ml, and this follow-up 68Ga-PSMA PET/CT scan showed predominant disease progression in the known metastatic bone lesions as the previous right acetabular bone lesions currently involving the whole right hemipelvis, with relatively stable appearance of the known metastatic pelvic lymphadenopathy (Figure 1).